On September 30, 2025, Edesa Biotech, Inc. reported an amendment to a multi-year funding agreement with the Government of Canada, extending the completion date to December 31, 2028, and modifying the repayment schedule to begin in 2032, concerning their Phase 3 study for the drug EB05.